Brokerages Expect POINT Biopharma Global Inc. (NASDAQ:PNT) Will Post Earnings of -$0.17 Per Share

Brokerages expect POINT Biopharma Global Inc. (NASDAQ:PNT) to post earnings per share of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for POINT Biopharma Global’s earnings, with estimates ranging from ($0.30) to ($0.10). The company is scheduled to issue its next earnings results on Friday, November 12th.

On average, analysts expect that POINT Biopharma Global will report full year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.37). For the next year, analysts forecast that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.39) to ($0.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for POINT Biopharma Global.

POINT Biopharma Global (NASDAQ:PNT) last posted its quarterly earnings data on Thursday, August 12th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01.

A number of equities research analysts have weighed in on PNT shares. Cowen began coverage on POINT Biopharma Global in a research note on Thursday, July 29th. They set an “outperform” rating for the company. Piper Sandler initiated coverage on shares of POINT Biopharma Global in a research note on Monday, July 26th. They set an “overweight” rating and a $17.00 price objective on the stock. Zacks Investment Research lowered shares of POINT Biopharma Global from a “hold” rating to a “sell” rating in a research note on Tuesday, September 28th. Finally, Jefferies Financial Group assumed coverage on shares of POINT Biopharma Global in a research note on Tuesday, July 27th. They set a “hold” rating and a $8.00 price objective on the stock.

Shares of PNT opened at $8.08 on Monday. POINT Biopharma Global has a 12 month low of $6.64 and a 12 month high of $18.08. The stock’s 50-day moving average is $9.06.

POINT Biopharma Global Company Profile

POINT Biopharma Global Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a.

See Also: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on POINT Biopharma Global (PNT)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for POINT Biopharma Global (NASDAQ:PNT)

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with's FREE daily email newsletter.